单倍体TCRαβ+/CD19+去除造血干细胞移植治疗儿童及年轻范可尼贫血患者
这项前瞻性单中心2期试验纳入24例缺乏HLA相合同胞或无关供者的范可尼贫血患者,接受HLA单倍体TCRαβ+/CD19+细胞去除造血干细胞移植。22例(91.6%)获得持续原发植入,中位随访5.2年,总生存概率100%,无事件生存概率86.3%(95%CI 62.8%-95.4%)。
要点
- 22/24例(91.6%)获得持续原发植入,中性粒细胞中位植入12天,血小板中位植入10天。
- 1-2级急性GVHD累积发生率17.4%(95%CI 5.5%-35.5%),慢性GVHD为5.5%(95%CI 0.8%-33.4%)。
- 中位随访5.2年,总生存概率100%,无事件生存概率86.3%(95%CI 62.8%-95.4%)。
核心结论
- 在缺乏HLA相合供者的范可尼贫血患者中,单倍体TCRαβ+/CD19+去除造血干细胞移植可实现高植入率和良好生存。
研究设计与样本
- 前瞻性单中心2期试验,纳入24例缺乏HLA相合同胞或无关供者的范可尼贫血儿童及年轻成人。
主要发现
- 22例(91.6%)获得持续原发植入,中性粒细胞中位恢复时间12天(范围9-15天),血小板中位恢复时间10天(范围7-14天)。
- 1-2级急性GVHD累积发生率17.4%(95%CI 5.5%-35.5%),慢性GVHD累积发生率5.5%(95%CI 0.8%-33.4%)。
- 中位随访5.2年(范围0.3-8.7年),总生存概率100%,无事件生存概率86.3%(95%CI 62.8%-95.4%)。
- 2例原发植入失败患者随后接受另一亲本来源的造血干细胞移植并成功植入。
关键数值与推荐
- 预处理方案包含氟达拉滨、低剂量环磷酰胺,大多数患者联合单次照射,耐受良好,未观察到致命性移植相关毒性。
临床怎么用
- 对于无HLA相合供者的范可尼贫血患者,可考虑单倍体TCRαβ+/CD19+去除造血干细胞移植。
局限性
- 单中心、小样本(24例)2期试验,结果需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report on the outcome of 24 patients with Fanconi anemia (FA) lacking an HLA matched related or unrelated donor, given an HLA-haploidentical T-cell receptor αβ (TCRαβ+) and CD19+ cell-depleted hematopoietic stem cell transplantation (HSCT) in the context of a prospective, single-center phase 2 trial. Sustained primary engraftment was achieved in 22 (91.6%) of 24 patients, with median time to neutrophil recovery of 12 days (range, 9-15 days) and platelet recovery of 10 days (range, 7-14 days). Cumulative incidences of grade 1 to 2 acute graft-versus-host disease (GVHD) and chronic GVHD were 17.4% (95% confidence interval [CI], 5.5%-35.5%) and 5.5% (95% CI, 0.8%-33.4%), respectively. The conditioning regimen, which included fludarabine, low-dose cyclophosphamide and, in most patients, single-dose irradiation was well tolerated; no fatal transplant-related toxicity was observed. With a median follow-up of 5.2 years (range, 0.3-8.7 years), the overall and event-free survival probabilities were 100% and 86.3% (95% CI, 62.8%-95.4%), respectively (2 graft failures and 1 case of poor graft function were considered as events). The 2 patients who experienced primary graft failure underwent a subsequent successful HSCT from the other parent. This is the first report of FA patients given TCRαβ+/CD19+-depleted haplo-HSCT in the context of a prospective trial, and the largest series of T-cell-depleted haplo-HSCT in FA reported to date. This trial was registered at www.clinicaltrials.gov as #NCT01810120.
引用
- Strocchio L, Pagliara D, Algeri M, et al. HLA-haploidentical TCRαβ+/CD19+-depleted stem cell transplantation in children and young adults with Fanconi anemia. Blood Adv. 2021. PMID: 33656536. doi:10.1182/bloodadvances.2020003707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。